Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Paclitaxel
Drug ID BADD_D01653
Description Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Indications and Usage Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Marketing Status approved; vet_approved
ATC Code L01CD01
DrugBank ID DB01229
KEGG ID D00491
MeSH ID D017239
PubChem ID 36314
TTD Drug ID D0C4RB
NDC Product Code 0703-3213; 52222-0001; 65129-1308; 68083-179; 69539-159; 62422-0004; 68001-516; 68083-178; 0703-4768; 68554-0061; 46708-622; 47781-595; 62332-621; 62332-622; 63323-763; 72205-063; 60505-6230; 62332-620; 72205-062; 0517-4300; 0703-3216; 0703-3218; 17359-3055; 63126-902; 69539-158; 72205-061; 17359-4056; 49452-4961; 51446-0110; 59651-605; 0703-4764; 51446-0120; 46708-620; 61703-342; 68083-180; 0703-3217; 17359-4040; 62422-0002; 69539-157; 70860-215; 42533-111; 54893-0007; 65129-2039; 69443-022; 16714-137; 68817-134; 70860-200; 17359-4055; 65892-002; 24979-710; 46708-621
UNII P88XT4IS4D
Synonyms Paclitaxel | Anzatax | NSC-125973 | NSC 125973 | NSC125973 | Taxol | Taxol A | Bris Taxol | Taxol, Bris | Paclitaxel, (4 alpha)-Isomer | Paxene | Praxel | 7-epi-Taxol | 7 epi Taxol | Onxol
Chemical Information
Molecular Formula C47H51NO14
CAS Registry Number 33069-62-4
SMILES CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6) O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Type IV hypersensitivity reaction10.01.03.0220.000112%Not Available
Tumour necrosis24.04.02.013; 16.32.03.009--Not Available
Skin burning sensation23.03.03.021; 17.02.06.0090.000414%Not Available
Infusion site reaction12.07.05.006; 08.02.05.005--Not Available
Necrotising enterocolitis neonatal18.04.11.002; 07.08.03.011--Not Available
Haemorrhage24.07.01.002--Not Available
Infusion site inflammation12.07.05.020; 08.02.05.020--Not Available
Faecaloma07.01.03.0040.000280%Not Available
Pulmonary mass22.02.07.004--Not Available
Distal intestinal obstruction syndrome07.13.01.0060.000336%Not Available
Cutaneous lupus erythematosus15.06.02.007; 23.03.02.008; 10.04.03.0070.000224%Not Available
Pneumatosis intestinalis07.11.01.0430.000280%Not Available
Temperature intolerance08.01.09.0220.000168%Not Available
Urine odour abnormal20.02.01.0200.000168%Not Available
Daydreaming19.21.02.0050.000168%Not Available
Hypoaesthesia oral17.02.06.021; 07.05.05.003--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000560%Not Available
Toxic skin eruption12.03.01.073; 23.03.05.003; 10.01.01.0080.000672%Not Available
Cancer pain16.32.03.004--Not Available
Metabolic disorder14.11.01.0010.000112%Not Available
Pulseless electrical activity02.03.04.0200.000392%Not Available
Cystoid macular oedema06.04.06.010; 12.02.02.0050.003134%Not Available
Nail pigmentation23.02.05.007--Not Available
Skin oedema23.06.04.001--Not Available
Thyroid mass05.02.01.003--Not Available
Bicytopenia01.03.03.0100.000112%Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000280%Not Available
Nail toxicity23.02.05.016; 12.03.01.0450.000392%Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000672%Not Available
The 21th Page    First    Pre   21 22 23 24 25    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene